HC Wainwright Issues Optimistic Outlook for ACRS Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright lifted their Q1 2026 earnings estimates for Aclaris Therapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.50) EPS.

A number of other analysts have also recently commented on ACRS. Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Craig Hallum began coverage on shares of Aclaris Therapeutics in a research report on Friday, January 30th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Trading Down 3.0%

Shares of ACRS stock opened at $3.58 on Monday. The stock has a 50-day moving average of $3.43 and a 200-day moving average of $2.79. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89. The stock has a market cap of $431.75 million, a price-to-earnings ratio of -6.75 and a beta of 0.88.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The business had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.07 million.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently made changes to their positions in ACRS. Millennium Management LLC grew its position in shares of Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after purchasing an additional 2,175,101 shares in the last quarter. Kotler Kevin purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter worth $5,135,000. Geode Capital Management LLC boosted its stake in Aclaris Therapeutics by 108.4% during the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after buying an additional 1,282,042 shares during the period. Ameriprise Financial Inc. purchased a new position in Aclaris Therapeutics during the third quarter worth about $2,428,000. Finally, Three Bridge Wealth Advisors LLC bought a new stake in shares of Aclaris Therapeutics during the 3rd quarter valued at about $1,358,000. 98.34% of the stock is owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.